Acute Myelogenous Leukemia (AML)

Abbott RealTime IDH2

For more information, contact Abbott.

CONTACT
Product Name Unit Size Order Number GTIN
Product Description
Product Description

Abbott RealTime IDH2 is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding nine IDH2 R140 and R172 mutations (R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W) in DNA extracted from human bone marrow (EDTA collection tubes) or blood (EDTA collection tubes).

Abbott RealTime IDH2 is for use with the Abbott m2000rt System. Abbott RealTime IDH2 consists of two kits:

  • Abbott RealTime IDH2 Amplification Reagent Kit (List No. 08N82‑090) That includes 9 vials sufficient for 24 tests:
    • Oligonucleotide Regent 1 to 4 (each vial 0.880 mL)
    • DNA Polymerase (4 vials – 0.051 mL/vial))
    • Activation Reagent (1 vial – 1.220 mL/vial))
  • Abbott RealTime IDH2 Control Kit (List No. 08N82‑080)). That includes 10 vials sufficient for 5 runs:
    • Negative Control (5 vials – 0.210 mL / vial)
    • Positive Control (5 vials – 0210 mL / vial).


Intended Use

Abbott RealTime IDH2 is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding nine IDH2 R140 and R172 mutations (R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W) in DNA extracted from human blood (EDTA) or bone marrow (EDTA). Abbott RealTime IDH2 is for use with the Abbott m2000rt System.

Indications For Use
Abbott RealTime IDH2 is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFA® (enasidenib).

ASSAY PROTOCOL
The Abbott RealTime IDH2 assay protocol includes the following steps:
  1. Manual preparation (ie, DNA extraction) of samples (specimens and controls) using the Abbott mSample Preparation SystemDNA (List No. 06K12 24) reagents to isolate and purify sample DNA.
  2. PCR assay setup using the sample eluates and the Abbott RealTime IDH2 Amplification Reagent Kit.
  3. Amplification/detection on the Abbott m2000rt instrument.


Specimens for Abbott RealTime IDH2 are processed manually using Abbott mSample Preparation SystemDNA (List No. 06K12 24) reagents to isolate and purify sample DNA.

The Abbott RealTime IDH2 amplification reagents are combined into four amplification master mixes.

The purified DNA sample is combined with the master mixes in an Abbott 96-Well Optical Reaction Plate, and the plate is transferred to the Abbott m2000rt instrument for amplification and detection of IDH2 mutations.

The specimen result is automatically reported on the Abbott m2000rt workstation at run completion. Assay controls are included within each run and are processed through the DNA extraction, amplification, and detection steps of the assay to assess run validity.

Software parameters specific to Abbott RealTime IDH2 are contained in an assay application specification file, which is loaded onto the Abbott m2000rt instrument by using a CD ROM disk.

Warnings and Precautions

Abbott RealTime IDH2 is for use with EDTA preserved human blood and EDTA preserved bone marrow aspirate.

Use only USP grade 190 to 200 proof ethanol (95 to 100% ethanol) to prepare the mWash 2DNA sample preparation reagent. Do not use ethanol that contains denaturants.

Limitations of the Assay

  • FOR IN VITRO DIAGNOSTIC USE
  • Abbott RealTime IDH2 is for use with human blood (EDTA) and bone marrow aspirate (EDTA) specimens only.
  • Optimal performance of this test requires appropriate specimen collection, handling, preparation, and storage (refer to the SPECIMEN COLLECTION, STORAGE, AND TRANSPORT TO THE TEST SITE section of this package insert).
  • Use of the Abbott RealTime IDH2 assay is limited to personnel who have been trained in the procedures of molecular diagnostic assays, the Abbott m2000rt instrument, and the manual sample preparation method for Abbott RealTime IDH2.
  • A “Not Detected” result does not preclude the presence of IDH2 mutations in the specimen. Assay results may be affected by inadequate specimen integrity, mutation content in the sample, and amount of amplifiable DNA.
  • The instrument and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the positive control or specimens must be controlled by good laboratory practices and careful adherence to the procedures specified in this package insert
  • Abbott RealTime IDH2 is designed to detect IDH2 R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W mutations. Specimens with results reported as “Not Detected” may contain mutations that are not targeted by the assay.
  • Analytical studies indicate that at high mutation percentage and high DNA input, the R140W probe can cross react with the R140G mutation. In this case, the software reports the mutation which is present at the highest level. All IDH2 mutations were correctly called in the analytical studies.
  • Components contained within a kit are intended to be used together. Do not mix components from different kit lots. For example, do not use the IDH2 Oligonucleotide Reagents from Amplification kit lot X with the Enzyme Reagent from Amplification kit lot Y.

Rx Only

To learn more about RealTime IDH2 please visit: https://www.molecular.abbott/us/en/products/oncology/realtime-idh2

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No